<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250847</url>
  </required_header>
  <id_info>
    <org_study_id>ARMS-4001</org_study_id>
    <nct_id>NCT01250847</nct_id>
  </id_info>
  <brief_title>Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)</brief_title>
  <acronym>ES-ARMS</acronym>
  <official_title>Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effects of 'Seroquel-XR' on the verbal&#xD;
      learning ability in people with at-risk mental state (ARMS) over a 12 week period. The verbal&#xD;
      learning ability will be indexed by delayed free recall score of CVLT(California Verbal&#xD;
      learning Test), a standard neuropsychological verbal memory tests.&#xD;
&#xD;
      The secondary objective is to assess the effects of 'Seroquel-XR' on other cognitive function&#xD;
      and psychiatric symptoms including psychotic, anhedonic symptoms, and impulsivity. The&#xD;
      cognitive function abilities will be measured by standard neuropsychological tests as&#xD;
      follows;&#xD;
&#xD;
        -  Working memory: verbal &amp; spatial 2-back test&#xD;
&#xD;
        -  Attention: Digit Span, 3-7 CPT(Continuous Performance Test)&#xD;
&#xD;
        -  Executive function: WCST (Wisconsin Card Sorting Test)&#xD;
&#xD;
        -  Visuo-spatial ability: Rey Complex Figure Task copy&#xD;
&#xD;
        -  Visuomotor speed and planning: Trail making test A &amp; B&#xD;
&#xD;
        -  Verbal fluency: Controlled Oral Word Association Test(COWAT) The scales of psychiatric&#xD;
           symptoms which will be used are as follows;&#xD;
&#xD;
        -  Psychotic symptoms: Scales of Prodromal scales (SOPS), Positive and negative syndrome&#xD;
           scale (PANSS)&#xD;
&#xD;
        -  Anhedonia: Social Anhedonia Scale (SAS), Physical Anhedonia Scale (PAS)&#xD;
&#xD;
        -  Social cognition: Ambiguous Intention Hostility Questionnaire (AIHQ)&#xD;
&#xD;
        -  Impulsivity: Barrett Impulsivity Scale (BIS)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>California Verbal Learning Test</measure>
    <time_frame>Baseline</time_frame>
    <description>Change from baseline in Verbal learning ability measured by CVLT at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>California Verbal Learning Test</measure>
    <time_frame>12th week</time_frame>
    <description>Change from baseline in Verbal learning ability measured by CVLT at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>verbal &amp; spatial 2-back test, Digit Span, 3-7 CPT, WCST, Rey-CFT, TMT A &amp; B, COWAT, SOPS, PANSS, SAS, PAS, AIHQ, BIS</measure>
    <time_frame>Baseline</time_frame>
    <description>Change from baseline in Working Memory etc. at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>verbal &amp; spatial 2-back test, Digit Span, 3-7 CPT, WCST, Rey-CFT, TMT A &amp; B, COWAT, SOPS, PANSS, SAS, PAS, AIHQ, BIS</measure>
    <time_frame>12th week</time_frame>
    <description>Change from baseline in working memory etc. at 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Abnormal Mental State</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Seroquel-XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schizophrenia Comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject with schizophrenia will be treated with standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The subjects will not be required to treat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine(Seroquel-XR) 50~800mg a day</intervention_name>
    <description>The only ARMS subjects will be given 50~800mg Seroquel-XR once daily for total of 12 weeks.</description>
    <arm_group_label>Healthy Control Comparator</arm_group_label>
    <arm_group_label>Schizophrenia Comparator</arm_group_label>
    <arm_group_label>Seroquel-XR</arm_group_label>
    <other_name>Quetiapine(Seroquel-XR)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written informed consent&#xD;
&#xD;
          2. Male and female aged 20 to 35 years&#xD;
&#xD;
          3. Able to understand and comply with the requirements of the study&#xD;
&#xD;
             ARMS:&#xD;
&#xD;
          4. Female patients of childbearing potential must be using a reliable method of&#xD;
             contraception and have a negative urine human chorionic gonadotropin (HCG) test at&#xD;
             enrolment&#xD;
&#xD;
          5. ARMS was diagnosed by Structured Interview for Prodromal Syndrome (SIPS) .&#xD;
&#xD;
        Schizophrenia subjects:&#xD;
&#xD;
        4. Schizophrenia was diagnosed by Diagnostic and Statistical Manual of Mental Disorders-&#xD;
        Fourth Edition (DSM-IV). Patients with schizophrenia had to have been ill no more than 5&#xD;
        years. Subjects had to be clinically stable and on stable antipsychotic therapy for at&#xD;
        least 4 weeks prior to baseline study.&#xD;
&#xD;
        Normal control:&#xD;
&#xD;
        4. Healthy volunteers who had no history of psychiatric illness and had no first degree&#xD;
        relative with psychotic symptoms were included for normal controls.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Any DSM-IV Axis I disorder not defined in the inclusion criteria. However, in the case&#xD;
             of ARMS, psychotic disorder NOS, major depressive disorder, obsessive-compulsive&#xD;
             disorder, and social phobia would be allowed.&#xD;
&#xD;
          3. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or&#xD;
             a danger to self or others&#xD;
&#xD;
          4. Known intolerance or lack of response to quetiapine fumarate, as judged by the&#xD;
             investigator&#xD;
&#xD;
          5. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding&#xD;
             enrolment including but not limited to: ketoconazole, itraconazole, fluconazole,&#xD;
             erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,&#xD;
             fluvoxamine and saquinavir&#xD;
&#xD;
          6. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding&#xD;
             enrolment including but not limited to: phenytoin, carbamazepine, barbiturates,&#xD;
             rifampin, St. John's Wort, and glucocorticoids&#xD;
&#xD;
          7. Administration of a depot antipsychotic injection within one dosing interval (for the&#xD;
             depot) before randomisation&#xD;
&#xD;
          8. Substance or alcohol dependence at enrolment (except dependence in full remission, and&#xD;
             except for caffeine or nicotine dependence), as defined by DSM-IV criteria&#xD;
&#xD;
          9. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV&#xD;
             criteria within 4 weeks prior to enrolment&#xD;
&#xD;
         10. Medical conditions that would affect absorption, distribution, metabolism, or&#xD;
             excretion of study treatment&#xD;
&#xD;
         11. Unstable or inadequately treated medical illness (e.g. congestive heart failure,&#xD;
             angina pectoris, hypertension) as judged by the investigator&#xD;
&#xD;
         12. Involvement in the planning and conduct of the study&#xD;
&#xD;
         13. Previous enrolment or randomisation of treatment in the present study.&#xD;
&#xD;
         14. Participation in another drug trial within 4 weeks prior enrolment into this study or&#xD;
             longer in accordance with local requirements&#xD;
&#xD;
         15. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:&#xD;
&#xD;
             Unstable DM defined as enrolment glycosylated hemoglobin (HbA1c) more than 8.5&#xD;
             percent.&#xD;
&#xD;
             Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.&#xD;
&#xD;
             Not under physician care for DM Physician responsible for patient's DM care has not&#xD;
             indicated that patient's DM is controlled.&#xD;
&#xD;
             Physician responsible for patient's DM care has not approved patient's participation&#xD;
             in the study Has not been on the same dose of oral hypoglycaemic drug(s) and(or) diet&#xD;
             for the 4 weeks prior to randomisation. For thiazolidinediones (glitazones) this&#xD;
             period should not be less than 8 weeks.&#xD;
&#xD;
             Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than&#xD;
             10 percent above or below their mean dose in the preceding 4 weeks Note: If a diabetic&#xD;
             patient meets one of these criteria, the patient is to be excluded even if the&#xD;
             treating physician believes that the patient is stable and can participate in the&#xD;
             study.&#xD;
&#xD;
         16. An absolute neutrophil count (ANC) of 1.5 folded 109 per liter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk Kyoon An, MD, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suk Kyoon An, MD, Ph D.</last_name>
    <phone>+82 17 349 8275</phone>
    <email>ansk@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Mental Health Hospital</name>
      <address>
        <city>Gwangju-si</city>
        <zip>464-100</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SuYoung Lee, MD</last_name>
      <phone>+82 31 760 9405</phone>
      <email>LEESUYOUNG@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Suk Kyoon An, MD, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SuYoung Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Kyoon An, MD, Ph D</last_name>
      <phone>+82 17 349 8275</phone>
      <email>ansk@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Suk Kyoon An, MD, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>August 18, 2011</last_update_submitted>
  <last_update_submitted_qc>August 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Suk Kyoon An</name_title>
    <organization>Severance Hospital</organization>
  </responsible_party>
  <keyword>ARMS</keyword>
  <keyword>Ultra High Risk</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Verbal memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

